top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Bit Size News May 13th - 17th

Early-stage antibody company bought for $850M & 9 more updates...👇

Want a list of segmented biopharma companies or access to our online platform? Get more info about our data and how it can help with sales and market intelligence

🎯 → Approvals

🔬 → New data

🤝 → M&A activity


🎯 FDA approved Imdeltra™ (Tarlatamab-DLLE) for the treatment of extensive-stage small cell lung cancer.  


🎯 Announced FDA approval of one of the first HPV self-collection solutions. 

BioCryst Pharmaceuticals

🎯 ORLADEYO® (berotralstat), a medication designed to prevent swelling attacks in adults and adolescents with hereditary angioedema (HAE), has been approved in Mexico.


🔬 Sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‑19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised patient population in the Ph3 SUPERNOVA trial.

Pliant Therapeutics 

🔬 Topline data reported from the Ph2a collagen PET imaging trial in patients with IPF showed that Bexotegrast 160 mg, administered over 12 weeks, reduced lung collagen, improved lung function (FVC), and lessened cough severity compared to placebo. The treatment was well-tolerated with no serious adverse events reported.


🔬 Demonstrated statistically significant and clinically meaningful improvements in the primary efficacy endpoint and all secondary endpoints, the primary results from the SEQUOIA-HCM trial were reported at the European Society of Cardiology Heart Failure 2024 Congress. These results remained consistent across all prespecified subgroups.

Novartis &  MorphoSys

🤝  Met all tender offer conditions to acquire MorphoSys for EUR 68 per share in cash. 

Johnson & Johnson and Proteologix, Inc.

🤝  Agreed to acquire Proteologix for $850 million in cash with potential for additional milestone payments. Proteologix is a private company specializing in bispecific antibodies for immune-mediated diseases.

Aeterna Zentaris & Ceapro

🤝  Aeterna Zentaris updated terms for its merger with Ceapro Inc., adjusting the share exchange ratio and announcing warrant issuance for shareholders.


Interested in these updates? Get the full update each week → 


May 13-17, 2024

Article History:

RF, DV, DG (05/17/24)


bottom of page